Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harbeck

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trialK L Jhaveri, P Neven, M L Casalnuovo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2022
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)S Paluch-Shimon, F Cardoso, A H Partridge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expressionU Nitz, O Gluz, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trialsM Graeser, O Gluz, C Zu Eulenburg, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
ESMO Open|April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trialG Curigliano, J O'Shaughnessy, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2015
The effect of EUSOMA certification on quality of breast cancer careP A van Dam, M Tomatis, L Marotti, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trialK L Jhaveri, P Neven, M L Casalnuovo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2022
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)S Paluch-Shimon, F Cardoso, A H Partridge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expressionU Nitz, O Gluz, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trialsM Graeser, O Gluz, C Zu Eulenburg, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
ESMO Open|April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trialG Curigliano, J O'Shaughnessy, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2015
The effect of EUSOMA certification on quality of breast cancer careP A van Dam, M Tomatis, L Marotti, et al.
Pageof 15